Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2 [4286]
Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2
| SMILES |
C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccno1)c1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCCCC[N+]1=C(/C=C/C=C/C=C2/N(C)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)[O-])ccc21)C(N)=O |
| InChIKey |
VXLISXCVTHKWNE-XZFSOASESA-M |
| Sequence |
None |
Chemical Properties
| Hydrogen bond acceptors |
17 |
| Hydrogen bond donors |
10 |
| Rotatable bonds |
34 |
| Log P |
4.979 |
| Molecular weight (Da) |
1376.6 |
| Stereochemistry info |
unspecified |
Bioactivities
|
| Receptor |
Activity |
Source |
| Protein |
Gene |
Species |
Family |
Class |
Type |
Min |
Avg |
Max |
Database |
|
|
|
|
|
|
|
|
|
|
|
| Receptor |
Activity |
Source |
| Protein |
Gene |
Species |
Family |
Class |
Type |
Min |
Avg |
Max |
Database |
|
|
|
|
|
|
|
|
|
|
Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2
Drug properties
| Molecular type |
Peptide |
| Physiological/Surrogate |
Surrogate |
| Approved drug |
No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0
Compound is not listed as a drug.